Advertisement
Advertisement
U.S. markets open in 6 hours 59 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Alterity Therapeutics Limited (ATH.AX)

ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
0.01700.0000 (0.00%)
At close: 01:04PM AEST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0170
Open0.0170
Bid0.0160 x 59129200
Ask0.0170 x 100647600
Day's Range0.0160 - 0.0170
52 Week Range0.0130 - 0.0350
Volume130,943
Avg. Volume2,101,519
Market Cap40.917M
Beta (5Y Monthly)1.05
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for ATH.AX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Benzinga

      Alterity Therapeutics Highlights New Publications On ATH434 In Parkinson's Disease

      Alterity Therapeutics's (NASDAQ: ATHE) data in an animal model of Multiple System Atrophy (MSA) were published in the Journal of Parkinson's Disease. The publication describes a study evaluating the efficacy of ATH434 in genetically altered mice that develop manifestations of MSA. The investigation demonstrated that ATH434 treatment reduced both the toxic oligomeric and aggregated forms of α–synuclein, a central nervous system protein essential for the normal function of nerve cells. At the same

    Advertisement
    Advertisement